Affordability of Innovation –Cost-effectiveness and Budget Impact Analysis of Acoramidis in Transthyretin Amyloid Cardiomyopathy in the German Health-care System

Abstract

Background

Transthyretin amyloid cardiomyopathy (ATTR-CM) causes heart failure with substantial morbidity, mortality, and healthcare utilization. ATTRibute-CM showed that acoramidis improves clinical outcomes, but its cost-effectiveness and budget impact in the German statutory health insurance (SHI) system remain uncertain.